AnaptysBio, Inc. (ANAB)
NASDAQ·Healthcare·Biotechnology
$66.06
-0.68%
Mkt Cap $1.49B
EPS — Estimate vs Actual
Revenue — Estimate vs Actual
Quarterly History
| Q1 2026 Mar 3, 2026 | $87.04M | $108.25M | +24.37% | $0.89 | $1.58 | +77.53% | — | — |
| Q4 2025 Nov 4, 2025 | $21.92M | $76.32M | +248.19% | -$1.06 | $0.52 | +149.06% | — | — |
| Q3 2025 Aug 7, 2025 | $11.68M | $22.26M | +90.54% | -$1.50 | -$1.34 | +10.67% | — | — |
| Q2 2025 May 5, 2025 | $15.27M | $27.77M | +81.82% | -$1.30 | -$1.28 | +1.54% | — | — |
| Q1 2025 Feb 27, 2025 | $7.78M | $43.11M | +453.91% | -$1.55 | -$0.72 | +53.55% | — | — |
| Q4 2024 Nov 5, 2024 | $8.21M | $30.02M | +265.83% | -$1.72 | -$1.14 | +33.72% | — | — |
| Q3 2024 Aug 5, 2024 | $22.76M | $10.97M | -51.79% | -$1.20 | -$1.71 | -42.50% | — | — |
| Q2 2024 May 9, 2024 | $4.00M | $7.18M | +79.43% | -$1.54 | -$1.64 | -6.49% | — | — |
| Q1 2024 Mar 12, 2024 | $3.79M | $9.01M | +137.89% | -$1.60 | -$1.59 | +0.67% | — | — |
| Q4 2023 Nov 2, 2023 | $2.29M | $3.32M | +44.98% | -$1.72 | -$1.41 | +18.02% | — | — |
| Q3 2023 Aug 7, 2023 | $2.68M | $3.46M | +28.90% | -$1.70 | -$1.50 | +11.53% | — | — |
| Q2 2023 May 11, 2023 | $2.90M | $1.37M | -52.56% | -$1.04 | -$1.58 | -51.92% | — | — |
| Q1 2023 Mar 1, 2023 | $5.78M | $6.81M | +17.71% | -$0.92 | -$0.93 | -1.09% | — | — |
| Q4 2022 Nov 8, 2022 | $13.43M | $1.29M | -90.37% | -$0.47 | -$1.18 | -151.06% | — | — |
| Q3 2022 Aug 8, 2022 | $5.30M | $1.22M | -77.04% | -$0.98 | -$1.15 | -17.11% | — | — |
| Q2 2022 May 4, 2022 | $5.05M | $970.00K | -80.81% | -$0.99 | -$1.31 | -31.67% | — | — |
| Q1 2022 Mar 7, 2022 | $976.00K | $1.01M | +3.59% | $2.28 | -$1.13 | -149.56% | — | — |
| Q4 2021 Nov 4, 2021 | $7.60M | $20.89M | +174.87% | -$0.74 | -$0.24 | +67.57% | — | — |
| Q3 2021 Aug 9, 2021 | $28.88M | $30.03M | +3.97% | -$0.15 | -$0.02 | +86.67% | — | — |
| Q2 2021 May 4, 2021 | $9.50M | $11.25M | +18.39% | -$0.71 | -$0.66 | +7.04% | — | — |